Search

Displaying results 4921 - 4930 of 9670 in total
  1. Drug

    Echinacoside

    go.drugbank.com/drugs/DB15488
    Investigational

    [A184577] Echinacoside has demonstrated inhibition of apoptosis in neural cell lines, demonstrating potential for use in the treatment of neurological conditions.[A184592]

  2. Drug

    Esmirtazapine

    go.drugbank.com/drugs/DB06678
    Investigational

    Merck has terminated its internal clinical development program for esmirtazapine as of March 2010. … Esmirtazapine, known by the standardized identifier SCH 900265, was under development by Organon to treat insomnia and vasomotor symptoms associated with menopause.

  3. Drug

    Brasofensine

    go.drugbank.com/drugs/DB04857
    Experimental

    In November 2001, NeuroSearch confirmed that the drug's development was discontinued in favor of NS 2230.

  4. Drug

    Alfaxalone

    go.drugbank.com/drugs/DB11371
    ExperimentalVet approved

    Alfaxalone, also known as alphaxalone or alphaxolone, is a neuroactive steroid and general anaesthetic. … Along with alfadolone, it is also one of the constituents of anesthetic drug mixture althesin.

  5. Drug

    Hydroxystilbamidine

    go.drugbank.com/drugs/DB14753
    Approved

    Hydroxystilbamidine isethionate is used in the therapy of some patients with nonprogressive blastomycosis of the skin, and pulmonary or systemic blastomycosis in children, with fewer side effects than amphotericin B. Hydroxystilbamidine ...

  6. Drug

    Bardoxolone methyl

    go.drugbank.com/drugs/DB05983
    Investigational

  7. Drug

    NS-2359

    go.drugbank.com/drugs/DB05805
    Investigational

    Enhancing the function of the three neurotransmitters serotonin, noradrenalin and dopamine, NS2359 has a desired "triple-mode-of-action".

  8. Drug

    AZD3409

    go.drugbank.com/drugs/DB04893
    Experimental

    Phase I trials were initiated January 2003, and were ongoing as of February 2004. As of February 2007 the development of AZD3409 had been discontinued.

  9. Drug

    Linopristin

    go.drugbank.com/drugs/DB19296
    Experimental

    It is one part of the combination product NXL 103, along with [Virginiamycin M1]. … The combination product was under investigation in clinical trials NCT00653172 and NCT00949130 for treatment of various bacterial infections.

  10. Drug

    Rintodestrant

    go.drugbank.com/drugs/DB21472
    Investigational

    Rintodestrant has a monoisotopic molecular weight of 462.09 Da. … Rintodestrant is under investigation in clinical trial NCT03455270 (G1T48, an Oral SERD, Alone and in Combination With Palbociclib in ER-Positive, HER2-Negative Advanced Breast Cancer).